Valuation: Carmat SA

Market Cap 6.15M 7.17M 5.75M 5.26M 9.92M 687M 10.02M 68.03M 26.45M 345M 26.93M 26.34M 1.14B P/E 2023
-3.09x
P/E 2024 -0.95x
Enterprise Value 59.25M 69.13M 55.42M 50.67M 95.62M 6.62B 96.64M 656M 255M 3.32B 260M 254M 11B EV / Sales 2023
56.1x
EV / Sales 2024 13.5x
Free-Float
89.06%
Yield 2023 *
-
Yield 2024 -
Current year 0.1
Extreme 0.099
0.1
1 year 0.08
Extreme 0.085
0.2
3 years 0.08
Extreme 0.085
9.99
5 years 0.08
Extreme 0.085
31.7
10 years 0.08
Extreme 0.085
44.95
Manager TitleAgeSince
Chief Executive Officer 55 01/09/2016
Director of Finance/CFO - 12/12/2018
Chief Tech/Sci/R&D Officer - 01/04/2025
Director TitleAgeSince
Director/Board Member 55 -
Director/Board Member 68 02/01/2017
Director/Board Member 79 20/04/2017
Date Insider Type Main position Quantity % Market Cap.
13/3/25 Sell

Chairman

1,343,333 2.3347%
13/3/25 Buy

Chairman

1,343,333 2.3347%
29/5/24 Buy

Director

1,343,333 4.6122%
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--%-47.89%-98.58% 7.08M
-0.50%-1.17%-16.85%+19.88% 126B
-0.18%-2.93%-21.88%+1.79% 12.42B
+0.41%+0.02%+97.19%+152.93% 10.95B
-1.04%-8.13%-52.54%-69.79% 4.1B
+2.94%+3.55%-22.09%+54.01% 2.77B
-1.43%+7.43%-35.96%-71.44% 1.78B
-2.25%-2.62%-25.37%-14.55% 1.62B
-3.08%-5.02%-37.51%-38.93% 1.56B
Average -0.57%-0.34%-18.10%-7.19% 17.88B
Weighted average by Cap. -0.42%-1.03%-10.98%+23.91%

Financials

2023 2024
Net sales 3.84M 4.48M 3.59M 3.28M 6.19M 429M 6.26M 42.48M 16.52M 215M 16.81M 16.45M 712M 7.34M 8.57M 6.87M 6.28M 11.85M 821M 11.98M 81.3M 31.61M 412M 32.18M 31.48M 1.36B
Net income -53.87M -62.86M -50.39M -46.07M -86.94M -6.02B -87.87M -596M -232M -3.02B -236M -231M -10B -51.4M -59.97M -48.08M -43.96M -82.95M -5.74B -83.83M -569M -221M -2.88B -225M -220M -9.54B
Net Debt 49.64M 57.92M 46.43M 42.45M 80.11M 5.55B 80.96M 549M 214M 2.78B 217M 213M 9.21B 53.1M 61.96M 49.68M 45.42M 85.7M 5.93B 86.61M 588M 229M 2.98B 233M 228M 9.86B
Logo Carmat SA
Carmat SA, formerly known as Carmat SAS is a France-based company engaged in the development and production of heart prosthesis. The Company is developing an orthotopic and biocompatible artificial heart which works like a natural heart, and which is hydraulically activated. It specializes in the development of a fully implantable orthotopic artificial heart, its electrical power supply system, and its telediagnosis system. The Company formed a network of partnerships with hospitals and various scientific companies, such as The Georges Pompidou European Hospital, The Marie Lannelongue Surgical Center, The Hospital Charles Nicolle of Rouen, Dedienne Sante, PaxiTech, Vignal Artru Industries, French Vessels, and Blood Institute, Laboratoire de Recherche Biochirurgicale and others.
Employees
153
  1. Stock Market
  2. Stocks
  3. ALCAR Stock